256 related articles for article (PubMed ID: 18713089)
1. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
[TBL] [Abstract][Full Text] [Related]
2. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
Safdar Z
Respir Med; 2009 Nov; 103(11):1688-92. PubMed ID: 19539456
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
4. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
5. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
6. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.
Keogh AM; McNeil KD; Wlodarczyk J; Gabbay E; Williams TJ
J Heart Lung Transplant; 2007 Feb; 26(2):181-7. PubMed ID: 17258153
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Monfredi O; Griffiths L; Clarke B; Mahadevan VS
Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
[TBL] [Abstract][Full Text] [Related]
10. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension.
Mok MY; Tsang PL; Lam YM; Lo Y; Wong WS; Lau CS
Lupus; 2007; 16(4):279-85. PubMed ID: 17439935
[TBL] [Abstract][Full Text] [Related]
11. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
12. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
13. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
[TBL] [Abstract][Full Text] [Related]
14. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
15. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
[TBL] [Abstract][Full Text] [Related]
16. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
17. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
Duffels MG; Vis JC; van Loon RL; Nieuwkerk PT; van Dijk AP; Hoendermis ES; de Bruin-Bon RH; Bouma BJ; Bresser P; Berger RM; Mulder BJ
Am J Cardiol; 2009 May; 103(9):1309-15. PubMed ID: 19406277
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
